$AVTX
Avalo Therapeutics, Inc. Stock $avtx

$avtx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000162828022028538 Filed on November 07, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q4
Revenue	$896.0K	$14.95M	$219.0K
YoY Change	309.13%	1007.33%	-85.36%
Cost Of Revenue	$620.0K	$528.0K	$424.0K
YoY Change	46.23%	-41.85%	433.87%
Gross Profit	$276.0K	$14.42M	-$205.0K
YoY Change	-234.63%	3162.67%	-114.47%
Gross Profit Margin	30.8%	96.47%	-93.61%
Selling, General & Admin	$2.959M	$3.284M	$5.981M
YoY Change	-50.53%	-44.58%	29.51%
% of Gross Profit	1072.1%	22.77%
Research & Development	$6.172M	$7.042M	$11.51M
YoY Change	-46.38%	-33.26%	-8.94%
% of Gross Profit	2236.23%	48.83%
Depreciation & Amortization	$35.00K	$34.00K	$295.0K
YoY Change	-88.14%	-92.53%	-45.2%
% of Gross Profit	12.68%	0.24%
Operating Expenses	$9.131M	$10.33M	$17.76M
YoY Change	-48.58%	-37.33%	0.01%
Operating Profit	-$8.855M	$4.095M	-$17.96M
YoY Change	-50.7%	-124.87%	9.94%
Interest Expense	-$949.0K	-$898.0K	-$1.184M
YoY Change	-19.85%	-8.83%	-2522.75%
% of Operating Profit		-21.93%
Other Income/Expense, Net	$0.00	-$898.0K	$0.00
YoY Change		-10.2%	-100.0%
Pretax Income	-$9.804M	$3.197M	-$19.15M
YoY Change	-48.8%	-118.31%	17.27%
Income Tax	$8.000K	$5.000K	-$16.00K
% Of Pretax Income		0.16%
Net Earnings	-$9.812M	$3.192M	-$19.20M
YoY Change	-48.89%	-118.35%	22.72%
Net Earnings / Revenue	-1095.09%	21.35%	-8765.3%
Basic Earnings Per Share		$0.34
Diluted Earnings Per Share	-$1.04	$339.1K	-$2.018M
COMMON SHARES
Basic Shares Outstanding	9.414M shares	9.414M shares	112.3M shares
Diluted Shares Outstanding		9.414M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.17M	$16.94M	$54.59M
YoY Change	-75.87%	-76.31%	188.51%
Cash & Equivalents	$13.17M	$16.90M	$54.59M
Short-Term Investments
Other Short-Term Assets	$1.305M	$1.171M	$2.423M
YoY Change	-46.14%	-25.51%	-10.17%
Inventory	$20.00K	$22.00K	$38.00K
Prepaid Expenses
Receivables	$0.00	$0.00	$1.060M
Other Receivables	$1.919M	$1.314M	$3.739M
Total Short-Term Assets	$16.42M	$19.45M	$61.85M
YoY Change	-73.46%	-74.74%	137.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.411M	$2.507M	$2.695M
YoY Change	-10.54%	77.8%	67.7%
Goodwill	$14.41M	$14.41M	$14.41M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$0.00	$0.00	$38.00K
YoY Change	-100.0%	-100.0%	-97.6%
Long-Term Investments
YoY Change
Other Assets	$131.0K	$181.0K	$1.227M
YoY Change	-89.32%	-91.87%	725.48%
Total Long-Term Assets	$16.95M	$17.10M	$18.37M
YoY Change	-7.72%	-6.83%	3.49%
TOTAL ASSETS
Total Short-Term Assets	$16.42M	$19.45M	$61.85M
Total Long-Term Assets	$16.95M	$17.10M	$18.37M
Total Assets	$33.37M	$36.55M	$80.21M
YoY Change	-58.4%	-61.67%	83.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.882M	$1.447M	$3.369M
YoY Change	-14.46%	-59.45%	30.89%
Accrued Expenses	$12.71M	$13.30M	$16.14M
YoY Change	-21.3%	-10.2%	42.74%
Deferred Revenue	$88.00K	$400.0K	$0.00
YoY Change
Short-Term Debt	$0.00	$2.564M	$0.00
YoY Change
Long-Term Debt Due	$5.930M	$2.564M
YoY Change
Total Short-Term Liabilities	$22.11M	$18.15M	$19.89M
YoY Change	11.19%	-4.67%	30.63%
LONG-TERM LIABILITIES
Long-Term Debt	$13.49M	$16.50M	$32.83M
YoY Change	-58.93%	-49.2%
Other Long-Term Liabilities	$1.711M	$1.791M	$2.298M
YoY Change	-25.54%	28.3%	22.36%
Total Long-Term Liabilities	$1.711M	$1.791M	$2.298M
YoY Change	-25.54%	28.3%	22.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.11M	$18.15M	$19.89M
Total Long-Term Liabilities	$1.711M	$1.791M	$2.298M
Total Liabilities	$44.28M	$38.58M	$57.13M
YoY Change	-22.49%	-29.92%	197.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$303.8M	-$294.0M	-$262.2M
YoY Change	15.89%	20.99%	47.46%
Common Stock	$9.000K	$9.000K	$9.000K
YoY Change	0.0%	-91.96%	-88.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$10.92M	-$2.028M	$23.08M
YoY Change
Total Liabilities & Shareholders Equity	$33.37M	$36.55M	$80.21M
YoY Change	-58.4%	-61.67%	83.33%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q4
OPERATING ACTIVITIES
Net Income	-$9.812M	$3.192M	-$19.20M
YoY Change	-48.89%	-118.35%	22.72%
Depreciation, Depletion And Amortization	$35.00K	$34.00K	$295.0K
YoY Change	-88.14%	-92.53%	-45.2%
Cash From Operating Activities	-$3.940M	$5.726M	-$17.10M
YoY Change	-76.96%	-135.15%	18.94%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$39.00K	-$11.00K
YoY Change	-100.0%	-51.85%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	$0.00	-$39.00K	-$11.00K
YoY Change	-100.0%	-51.85%	-97.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	82.00K	0.000	76.00K
YoY Change	7.89%	-100.0%	-62.19%
NET CHANGE
Cash From Operating Activities	-3.940M	5.726M	-17.10M
Cash From Investing Activities	0.000	-39.00K	-11.00K
Cash From Financing Activities	82.00K	0.000	76.00K
Net Change In Cash	-3.858M	5.687M	-17.03M
YoY Change	-77.35%	-81.81%	16.94%
FREE CASH FLOW
Cash From Operating Activities	-$3.940M	$5.726M	-$17.10M
Capital Expenditures	$0.00	-$39.00K	-$11.00K
Free Cash Flow	-$3.940M	$5.765M	-$17.09M
YoY Change	-76.94%	-135.57%	18.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001534120
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0833
CY2022Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0833
CY2022Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0833
CY2022Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0833
	avtx	Stockholders Equity Note Preferred Stock Conversion Ratio StockholdersEquityNotePreferredStockConversionRatio	2.38
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.avalotherapeutics.com/20220930#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.avalotherapeutics.com/20220930#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2022Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0.0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0.0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0.0	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37590
	dei	Entity Registrant Name EntityRegistrantName	AVALO THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-0705648
	dei	Entity Address Address Line1 EntityAddressAddressLine1	540 Gaither Road, Suite 400
	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
	dei	City Area Code CityAreaCode	410
	dei	Local Phone Number LocalPhoneNumber	522-8707
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	AVTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9414104	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16943000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54585000	usd
CY2022Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1060000	usd
CY2022Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1314000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3739000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	22000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	38000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1118000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2372000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	53000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	51000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	19450000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	61845000	usd
CY2022Q3	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2507000	usd
CY2021Q4	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2695000	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Assets DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets	0	usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Assets DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets	1000000	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	38000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	14409000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	14409000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	227000	usd
CY2022Q3	us-gaap	Assets Assets	36547000	usd
CY2021Q4	us-gaap	Assets Assets	80214000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1447000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3369000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	442000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13696000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	16519000	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	2564000	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	18149000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19888000	usd
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	16502000	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	32833000	usd
CY2022Q3	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	2000000	usd
CY2021Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	2000000	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	133000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	113000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1791000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2298000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	38575000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	57132000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9414104	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9414104	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9399517	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9399517	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	291975000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	285239000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-294012000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-262166000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2028000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23082000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36547000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80214000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14949000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1350000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17155000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5179000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	528000	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	908000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2814000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1067000	usd
CY2022Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7042000	usd
CY2021Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	10551000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	25136000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	48325000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3284000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5926000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17752000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18677000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	428000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1281000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	10854000	usd
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	17813000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	45740000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	69350000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	4095000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16463000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-28585000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-64171000	usd
CY2022Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-898000	usd
CY2021Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-985000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-3221000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1207000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-898000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1000000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3241000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1227000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3197000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17463000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31826000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-65398000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-180000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	3192000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-17471000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-31846000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-65218000	usd
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	usd
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	76000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	38000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	3192000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-17395000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31846000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-65180000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-5951000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	731000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	3192000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2028000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23082000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	25000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6711000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31846000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2028000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	21588000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1758000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-17395000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	40309000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	24562000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	29046000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	861000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1568000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	0	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	207000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6280000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-65180000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	40309000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31846000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-65180000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	131000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1362000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6711000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6280000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1040000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	445000	usd
	us-gaap	Contract With Customer Receivable Credit Loss Expense Reversal ContractWithCustomerReceivableCreditLossExpenseReversal	1000000	usd
	us-gaap	Contract With Customer Receivable Credit Loss Expense Reversal ContractWithCustomerReceivableCreditLossExpenseReversal	0	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	20000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	40000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1060000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-742000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2425000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	269000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2000000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-16000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1254000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1252000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1922000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	994000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	442000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability		usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-3144000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	2604000	usd
	avtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	2000	usd
	avtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-50000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22811000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53793000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	95000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	102000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-95000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-102000	usd
	avtx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	usd
	avtx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	37653000	usd
	avtx	Proceeds From Venture Debt Financing Agreement ProceedsFromVentureDebtFinancingAgreement	0	usd
	avtx	Proceeds From Venture Debt Financing Agreement ProceedsFromVentureDebtFinancingAgreement	32900000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	14806000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	usd
	avtx	Proceeds From Issuance Of Common Stock In Underwritten Public Offering ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering	0	usd
	avtx	Proceeds From Issuance Of Common Stock In Underwritten Public Offering ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering	29046000	usd
	avtx	Proceeds From Issuance Of Common Stock Through Atm Program ProceedsFromIssuanceOfCommonStockThroughATMProgram	0	usd
	avtx	Proceeds From Issuance Of Common Stock Through Atm Program ProceedsFromIssuanceOfCommonStockThroughATMProgram	5312000	usd
	avtx	Proceeds From Option Or Warrant Exercises ProceedsFromOptionOrWarrantExercises	0	usd
	avtx	Proceeds From Option Or Warrant Exercises ProceedsFromOptionOrWarrantExercises	1568000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	25000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	207000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-14781000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	106686000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-37687000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	52791000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54864000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19106000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17177000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71897000	usd
	us-gaap	Interest Paid Net InterestPaidNet	2256000	usd
	us-gaap	Interest Paid Net InterestPaidNet	796000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16943000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71506000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	53000	usd
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	164000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181000	usd
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	227000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17177000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71897000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Business <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Avalo Therapeutics, Inc. (the “Company” or “Avalo” or “we”) is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT network. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LIGHT (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ymphotoxin-like, exhibits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nducible expression, and competes with HSV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">lycoprotein D for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">erpesvirus Entry Mediator (“HVEM”), a receptor expressed by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin β receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (“BTLA”), and CD160 (collectively, the “LIGHT-signaling network” or the “LIGHT network”). Accumulating evidence points to the dysregulation of the LIGHT network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Avalo was incorporated in Delaware and commenced operation in 2011, and completed its initial public offering in October 2015. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 7, 2022, Avalo effected a 1-for-12 reverse stock split. The Company retroactively applied the reverse stock split to share and per share amounts for periods prior to July 7, 2022, including the unaudited condensed consolidated financial statements for the nine months ended September 30, 2022, three and nine months ended September 30, 2021, and the year ended December 31, 2021. Additionally, pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all of the Company’s outstanding options and warrants, and the number of shares authorized for issuance pursuant to the Company’s equity incentive plans have been reduced proportionately. Avalo retroactively applied such adjustments in the notes to the unaudited condensed consolidated financial statements for periods presented prior to July 7, 2022, including the nine months ended September 30, 2022, three and nine months ended September 30, 2021, and the year ended December 31, 2021. The reverse stock split did not reduce the number of authorized shares of common and preferred stock and did not alter the par value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to meet its cash flow needs, the Company applies a disciplined decision-making methodology as it evaluates the optimal allocation of the Company’s resources between investing in the Company’s existing pipeline assets and acquisitions or in-licensing of new assets. As of September 30, 2022, Avalo had $16.9 million in cash and cash equivalents. For the nine months ended September 30, 2022, Avalo generated a net loss of $31.8 million and negative cash flows from operations of $22.8 million. As of September 30, 2022, Avalo had an accumulated deficit of $294.0 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the second quarter of 2022, as collectively agreed upon with the Lenders (as defined below), the Company made a partial prepayment of $15.0 million ($14.8 million of which was applied to principal) on the notes (the “Notes) issued under its venture loan and security agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation (“Horizon”) and Powerscourt Investments XXV, LP (“Powerscourt”, and together with Horizon, the “Lenders”). Avalo intends to consider additional prepayments prior to principal loan amounts coming due, if collectively agreed upon with the Lenders. As of September 30, 2022, the carrying value of the Notes (as defined in Note 9) was $19.1 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern; however, losses are expected to continue as the Company continues to invest in its research and development pipeline assets. The Company will require additional financing to fund its operations and to continue to execute its business strategy within one year after the date the unaudited condensed consolidated financial statements included herein were issued. We anticipate that the cash and cash equivalents as of September 30, 2022 will not be sufficient for us to fund our product candidates through their next anticipated milestones, which include topline data from the AVTX-002 Phase 2 PEAK trial and pivotal data from the AVTX-803 LADDER trial, both expected in the first half of 2023. We will need to raise additional capital to reach these milestones. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To mitigate these conditions and to meet the Company’s capital requirements, management plans to use its current cash on hand along with some combination of the following: (i) dilutive and/or non-dilutive financings, (ii) out-licensing or strategic alliances/collaborations of its current pipeline assets, (iii) out-licensing or sale of its non-core assets, and (iv) federal and/or private grants. If the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates. Subject to limited exceptions, the Loan Agreement prohibits the Company from incurring certain additional indebtedness, making certain asset dispositions, and entering into certain mergers, acquisitions or other business combination transactions without the prior consent of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lenders. Additionally, the Loan Agreement contains certain covenants and certain other specified events that could result in an event of default, which if not cured or waived, could result in the immediate acceleration of all or a substantial portion of the outstanding Notes. As of the filing date of this Quarterly Report on Form 10-Q, the Company was not aware of any breach of covenants or occurrence of material adverse change, nor had it received any notice of event of default from the Lenders (refer to Note 9 of the condensed unaudited consolidated financial statements for more information).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company requires but is unable to obtain additional funding, the Company may be forced to make reductions in spending, delay, suspend, reduce or eliminate some or all of its planned research and development programs, or liquidate assets where possible. Due to the uncertainty regarding future financing and other potential options to raise additional funds, management has concluded that substantial doubt exists with respect to the Company’s ability to continue as a going concern within one year after the date that the financial statements in this Quarterly Report on Form 10-Q were issued. </span></div>Over the long term, the Company’s ultimate ability to achieve and maintain profitability will depend on, among other things, the development, regulatory approval, and commercialization of its pipeline assets, and the potential receipt and sale of any priority review vouchers it receives.
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16900000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31800000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22800000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-294000000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	400000	usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	700000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2000000	usd
CY2022Q3	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	14500000	usd
	avtx	Class Of Stock Number Of Classes Of Stock Outstanding ClassOfStockNumberOfClassesOfStockOutstanding	2	class_of_stock
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	3192000	usd
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	166	shares
	us-gaap	Net Income Loss NetIncomeLoss	-31846000	usd
	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	139747	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.012
CY2021Q4	avtx	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Exercised ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised	25740	shares
CY2022Q3	avtx	Lessee Operating Lease Number Of Leased Properties LesseeOperatingLeaseNumberOfLeasedProperties	2	property
	avtx	Lessee Operating Lease Remaining Lease Team LesseeOperatingLeaseRemainingLeaseTeam	P5Y9M18D
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1813000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2001000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	526000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	485000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1791000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2018000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2317000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2503000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.092
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	134000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	97000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	373000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	287000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	130000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	528000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	537000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	547000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	557000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	258000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	426000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2983000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	666000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2317000	usd
CY2022Q3	avtx	Accrued Research And Development AccruedResearchAndDevelopment	7094000	usd
CY2021Q4	avtx	Accrued Research And Development AccruedResearchAndDevelopment	8221000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2972000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4310000	usd
CY2022Q3	avtx	Accrued Selling General And Administrative Expenses AccruedSellingGeneralAndAdministrativeExpenses	903000	usd
CY2021Q4	avtx	Accrued Selling General And Administrative Expenses AccruedSellingGeneralAndAdministrativeExpenses	1386000	usd
CY2022Q3	avtx	Commercial Operations Current CommercialOperationsCurrent	1798000	usd
CY2021Q4	avtx	Commercial Operations Current CommercialOperationsCurrent	1733000	usd
CY2022Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	399000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	375000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	526000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	485000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	4000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	9000	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13696000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	16519000	usd
CY2022Q3	avtx	Number Of Class Of Stock Authorized NumberOfClassOfStockAuthorized	2	class_of_stock
CY2022Q3	avtx	Capital Stock Shares Authorized CapitalStockSharesAuthorized	205000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.012
CY2021Q4	avtx	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Exercised ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised	25740	shares
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	731000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1758000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6711000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6280000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000	usd
CY2019Q3	avtx	Royalty Agreement Payment Received RoyaltyAgreementPaymentReceived	2000000	usd
CY2019Q3	avtx	Royalty Agreement Period After Public Launch To Terminate Agreement RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement	P3Y
CY2019Q3	avtx	Royalty Agreement Buyout Option Percentage Of Net Present Value Of Royalty Payments RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments	0.75

Files In Submission

Name	View Source	Status
0001628280-22-028538-index-headers.html	Edgar Link	pending
0001628280-22-028538-index.html	Edgar Link	pending
0001628280-22-028538.txt	Edgar Link	pending
0001628280-22-028538-xbrl.zip	Edgar Link	pending
avtx-20220930.htm	Edgar Link	pending
avtx-20220930.xsd	Edgar Link	pending
avtx-20220930_g1.jpg	Edgar Link	pending
ex-101_apollolicenseagreem.htm	Edgar Link	pending
ex-103_apaxestherapeutics.htm	Edgar Link	pending
ex-312avtx3q2022.htm	Edgar Link	pending
ex-321avtx3q2022.htm	Edgar Link	pending
ex311avtx3q2022.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
avtx-20220930_cal.xml	Edgar Link	unprocessable
avtx-20220930_pre.xml	Edgar Link	unprocessable
avtx-20220930_def.xml	Edgar Link	unprocessable
avtx-20220930_lab.xml	Edgar Link	unprocessable
avtx-20220930_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVTX
Avalo Therapeutics, Inc. Stock $avtx

2022 Q4 Form 10-Q Financial Statement

#000162828022028538 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX Avalo Therapeutics, Inc. Stock $avtx

2022 Q4 Form 10-Q Financial Statement

#000162828022028538 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX
Avalo Therapeutics, Inc. Stock $avtx